| scholarly article | Q13442814 |
| P356 | DOI | 10.3816/CLC.2003.N.008 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S1525730411702959?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S1525730411702959?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 14609446 |
| P2093 | author name string | A. Alexopoulos | |
| N. Samaras | |||
| V. Georgoulias | |||
| M. Toumbis | |||
| A. Agelidou | |||
| A. Ardavanis | |||
| A. G. Pallis | |||
| C. Kourousis | |||
| E. Tzelepatiotis | |||
| G. Pavlakou | |||
| M. Agelidou | |||
| P. Ziotopoulos | |||
| S. Tzannes | |||
| P2860 | cites work | Reporting results of cancer treatment | Q29620070 |
| Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience | Q30810434 | ||
| Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer | Q33502457 | ||
| Current standards of care in small-cell and non-small-cell lung cancer | Q34399806 | ||
| Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) | Q36080076 | ||
| Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer | Q36702802 | ||
| Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer | Q40994604 | ||
| Relationships between the structure of taxol analogs and their antimitotic activity | Q48789967 | ||
| A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). | Q53527972 | ||
| Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. | Q53936099 | ||
| First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study | Q57905095 | ||
| Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer | Q72679565 | ||
| Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer | Q72679569 | ||
| Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival | Q74037394 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncology | Q162555 |
| docetaxel | Q420436 | ||
| P304 | page(s) | 288-293 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Clinical Lung Cancer | Q332299 |
| P1476 | title | Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study | |
| Docetaxel Versus Docetaxel/Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Analysis of a Multicenter, Randomized Phase III Study | |||
| P478 | volume | 4 |
| Q40294108 | Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy |
| Q53020454 | Does granulocyte colony-stimulating factor affect survival in patients with advanced non-small cell lung cancer? |
| Q41849135 | Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer |
| Q36580586 | Present and future of lung cancer vaccines |
| Q24200518 | Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease |
| Q24243664 | Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease |
Search more.